Quest wins approval to increase capacity for COVID-19

By LabPulse.com staff writers

July 30, 2020 -- Quest Diagnostics has received emergency use authorization from the U.S. Food and Drug Administration to test a new laboratory technique that could bolster its COVID-19 testing capacity.

The technique speeds up the process of extracting viral RNA from both individual and pooled patient specimens. It utilizes the Mag-Bind Viral RNA Xpress Kit from Omega Bio-Tek and the MagEx Star from Hamilton.

The method will expand the company's current capacity of 135,00 daily COVID-19 assays to 150,000 daily tests in August and 185,000 daily tests in September, according to the company. It can also reduce turnaround times for high-priority patients, which is crucial as surging demand has led to delays for Quest patients in recent weeks.

Five Quest laboratories in areas with high testing demand will run the new RNA extraction method. The extraction technique can be used with Quest's SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) diagnostic, which screens respiratory specimens.

FDA grants first coronavirus clearance for sample pooling to Quest
The U.S. Food and Drug Administration has granted Quest Diagnostics the first emergency use authorization for a SARS-CoV-2 molecular diagnostic for testing...
Quest overall testing volume, revenue decline
Quest Diagnostics reported an 18% decline in overall test volume as part of a look at its preliminary financial results from the second quarter and reported...
HPV, Pap cotesting best for cervical cancer detection in Quest study
Human papillomavirus (HPV) or Pap testing alone is less likely than the combination of both methods to detect cervical cancer, according to a Quest Diagnostics...
COVID-19 testing demand delays Quest's turnaround time
Demand for COVID-19 testing continues to increase, causing further turnaround time delays for Quest Diagnostics, according to a statement released by...
Quest's daily orders for COVID-19 tests outstrip capacity
Quest has reported that it is struggling to meet a surge in demand for molecular diagnostics for COVID-19, resulting in longer turnaround times for results.

Copyright © 2020 LabPulse.com

Last Updated ls 7/30/2020 3:28:21 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current